Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

BACKGROUND: Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS. Eligible patients were treatment-naive with stage IIIB or IV NSCLC. In addition, inclusion was l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwitter, Matjaz, Stanic, Karmen, Rajer, Mirjana, Kern, Izidor, Vrankar, Martina, Edelbaher, Natalija, Kovac, Viljem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230556/
https://www.ncbi.nlm.nih.gov/pubmed/25435849
http://dx.doi.org/10.2478/raon-2014-0038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230556/
https://www.ncbi.nlm.nih.gov/pubmed/25435849
http://dx.doi.org/10.2478/raon-2014-0038

Ejemplares similares